Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (14070)	11/12/2004 6:56:42 PM
From: The Dodgy Ticker	Respond to of 52153

Hi, rkrw, Why do you think PARS' drug will not be approved? I thought it was doing fine; did I miss something? Best regards, Bob

To: rkrw who wrote (14070)	11/12/2004 7:07:13 PM
From: tuck	Read Replies (1) \| Respond to of 52153

I'll agree with much of what you say, particularly, the No for Isis' Alicaforsen (1st generation antisense, has failed plenty already) and for APPX' Abraxane (iffy trial design). However my take was that Corgentech's E2F decoy would return good data, but run into a wary FDA, given the past issues with "gene therapy." Since the upcoming event concerns data, not approval, we disagree. Care to go public with your reasoning? Data not quite strong enough to support current valuation, rather than an outright failure, perhaps? PII data here: Message 20232809 for those interested (rkrw has seen it, of course). TIA & Cheers, Tuck